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Abstract
Background: To determine the impact of preexisting ischemic heart disease (IHD) and stroke on overall survival in
prostate cancer patients.
Methods: We conducted a cohort study of patients with incident prostate cancer registered in the Danish Cancer
Registry from 1997 through 2008. We identified patients diagnosed with IHD or stroke prior to the date of prostate
cancer diagnosis in the Danish National Patient Registry. We constructed Kaplan-Meier curves to analyze time to
death and Cox regression was used to estimate hazard ratios (HRs) to compare mortality rates by preexisting IHD
or stroke status, adjusting for age, stage, comorbidity, and calendar period.
Results: Of 30,721 prostate cancer patients, 4,276 (14%) had preexisting IHD and 1,331 (4%) preexisting stroke. Crude 1-
and 5-year survival rates were 85% and 44% in men without preexisting IHD or stroke, 81% and 36% in men with
preexisting IHD, and 78% and 27% in men with preexisting stroke. Adjusted HRs were 1.05 (95% CI 1.00-1.10) for
patients with IHD and 1.20 (95% CI 1.12-1.30) for patients with stroke compared with patients without preexisting IHD
or stroke.
Conclusions: Preexisting IHD had minimal impact on mortality in prostate cancer patients, whereas overall
mortality was 20% higher in prostate cancer patients with preexisting stroke compared to those without IHD or
stroke. These results highlight the importance of differentiating between various comorbidities.
Background
Prostate cancer is the most common malignancy in men
and the second most common cause of death from can-
cer in men in Western countries [1]. In Denmark, pros-
tate cancer accounts for 4% of all deaths in men [2]. The
median age of patients with newly diagnosed prostate
cancer is above70 years, and a large proportion of these
men have coexisting diseases (comorbidities) at the time
of prostate cancer diagnosis [3]. Several studies have
shown that comorbidity increases mortality in prostate
cancer patients [3-6]. In a Danish population-based
cohort study of prostate cancer patients diagnosed
between 1995 and 2006, comorbidity was present in
more than one-third of the patients and was a negative
prognostic factor [3]. In that study, prostate cancer survi-
val generally improved over time except among patients
with high levels of comorbidity. However, the study did
not address the impact of specific types of comorbidity.
Comorbidity may indirectly affect prognosis by influen-
cing choice of treatment; e.g. in men with localized pros-
tate cancer those with comorbidity tend to receive
conservative/nonsurgical treatment more often than
those without [4,7-9]. Cardiovascular diseases, including
ischemic heart disease (IHD) and stroke, are common
diseases and the leading causes of death in most Western
countries accounting for nearly half of all deaths in Eur-
ope (48%) [10] and of one third of all deaths in the US
(34%) [11]. During the last 30 years, mortality from
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European countries due to decreasing incidence com-
bined with improved treatments [10-14]. Still, little is
known on how preexisting IHD and stroke affect the sur-
vival in prostate cancer patients. The aim of this study
was therefore to estimate the prognostic impact of preex-
isting IHD and stroke in prostate cancer patients.
Accordingly, we conducted a large cohort study of Dan-
ish prostate cancer patients using nationwide registries.
Methods
Study population
We conducted this nationwide cohort study in Denmark,
which has 5.3 million inhabitants. Free tax-supported
health care is provided for all Danish residents by the
National Health Service. We retrieved data from the Dan-
ish Civil Registration System, the Danish Cancer Registry,
and the National Patient Registry. A unique 10-digit civil
registration number is assigned to all Danish residents by
the Central Office of Civil Registration, and this number
allows unambiguous linkage between all Danish registries
[15].
Identifying patients with prostate cancer
During the study period (1997-2008), no formal prostate
cancer screening program existed in Denmark. Men with
suspected or confirmed prostate cancer were referred to
departments of urology in public hospitals for examina-
tion, counselling, and treatment. We identified men with
prostate cancer through the Danish Cancer Registry [16].
This is a population-based, nationwide registry with data
on incident cancer in Denmark since 1943. Data include
civil registration number, diagnostic measures, and stage
at diagnosis. All diagnoses have been reclassified accord-
ing to the International Classification of Diseases 10
th
revision (ICD-10). We used ICD-10 code DC61.9 to iden-
tify patients with prostate cancer. Until 2003, disease
stage was recorded as localized, regional, or distant. After
2003, the stage was recorded using the TNM system. We
classified the stage as localized if T1-2, N0, M0, regional
if T3-4 or N1-3, M0, and distant if T1-4, N0-3, M1.
IHD and stroke
We obtained information on preexisting IHD and stroke
through the National Patient Registry [17]. This registry
contains data on all somatic hospital admissions since
1977 and on outpatient and emergency room visits since
1995. It includes dates of admission and discharge, surgical
procedures, and up to 20 diagnoses coded by physicians at
discharge according to ICD 8 until 1993 and ICD 10
thereafter. We identified all hospitalizations with primary
or secondary diagnoses of IHD (angina pectoris, acute
myocardial infarction, acute and chronic IHD, asympto-
matic IHD), and stroke (cerebral infarction and
unspecified stroke) recorded within 10 years prior to date
of prostate cancer diagnosis (see Table 1 for codes).
Other types of comorbidity
We used the Charlson comorbidity index [18] to
describe other types of comorbidity in the prostate can-
cer patients. We calculated the index score for each
patient based on previous diagnoses other than IHD,
stroke, or prostate cancer recorded in the National
Patient Registry recorded within ten years before the
prostate cancer diagnosis. We categorized the index
score into three comorbidity levels: 0 = none, 1-2 =
moderate, and ≥ 3 = high.
Mortality
Mortality and migration updates were obtained from the
Civil Registration System [15]. This system is updated
daily and contains information on vital status (dead or
alive), date of death, and postal address. When a Danish
citizen dies, the attending physician must report the
cause of death, and the events leading to death are
described by up to four ICD-10 diagnoses. We obtained
information on the primary cause of death for all
patients from 1997 to 2008 through the Danish Cause
of Death Registry, established in 1943.
Statistical analysis
Follow-up started at the date of prostate cancer diagno-
sis and continued until death or December 31
st 2008,
Table 1 ICD-8 and ICD-10 diagnosis codes of ischemic
heart disease and stroke
Diagnosis ICD-8 codes ICD-10 codes
Ischemic heart disease:
Angina pectoris 413.09,
413.99
DI20.x
Acute myocardial infarction 410.09,
410.99
DI21.x, DI22.x, DI23.
x
Acute ischemic heart disease 411.09,
411.99
DI24.x
Chronic ischemic heart disease 412.09,
412.99
DI25.x
Asymptomatic ischemic heart
disease
414.09,
414.99
Stroke:
Cerebral infarction DI63.x
Cerebral apoplexy (unspecified) DI64.x
Cerebral thrombosis 433.09,
433.99
Cerebral embolism 434.09,
434.99
Cerebral apoplexy 436.01,
436.90
Acute cerebrovascular disease 436.09,
436.99
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Page 2 of 7whichever occurred first. We constructed Kaplan-Meier
curves to illustrate time from prostate cancer diagnosis
to death. We used Cox regression analysis to estimate
hazard ratios (HRs) to compare time to death within 5
years after prostate cancer diagnosis in patients with
preexisting IHD or stroke compared with prostate can-
cer patients without IHD or stroke, while controlling for
age (categorized as 30-34, 35-39, 40-44, 45-49, 50-54,
55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85-100 years),
prostate cancer stage, study year, and other comorbid-
ities. In this analysis patients were followed until death,
five years of follow-up, or December 31st 2008, which-
ever came first. The analysis was stratified by age group:
30-59, 60-69, and ≥ 70 years. We also restricted the ana-
l y s i st op a t i e n t sw i t h o u to t h e r chronic diseases (Charl-
son comorbidity level = 0). Furthermore, we estimated
HRs for those diagnosed with IHD or stroke within 1
year before prostate cancer diagnosis compared with
those diagnosed 2-10 years before prostate cancer diag-
nosis. The assumptions for the Cox model were assessed
graphically and found appropriate. Estimates are pre-
sented with 95% confidence intervals (CI). Statistical
analyses were performed using STATA software (Ver-
sion 11, SE). The study was approved by the Danish
Data Protection Agency (Journal no. 2009-41-3793).
Results
We included 30,721 men with a primary diagnosis of
prostate cancer in Denmark between 1997 and 2008. The
median age at prostate cancer diagnosis was 72 years
(range, 34-100 years). At diagnosis, 14% (4,276) had pre-
existing IHD and 4% (1,331) preexisting stroke. Patients
with preexisting IHD or stroke were older, had higher
tumour stage, and higher levels of other comorbidities at
diagnosis than patients without IHD or stroke (Table 2).
Survival
Figure 1 shows crude survival in the three cohorts of
prostate cancer patients. Overall 1- and 5-year survival
for the entire cohort was 84.4% (95% CI, 84.0-84.8) and
41.7% (95% CI, 41.0-42.4), respectively. Crude 1- and 5-
year survival was lower for patients with preexisting IHD
or stroke compared with those without IHD or stroke.
Table 3 shows survival estimates for patient subgroups.
Mortality
A total of 13,851 (45%) prostate cancer patients died dur-
ing follow-up (mortality rate, 154 per 1,000 person-
years). Of those 2,067 had preexisting IHD (mortality
rate, 179 per 1,000 person-years) and 732 preexisting
stroke (mortality rate, 229 per 1,000 person-years). Pros-
tate cancer patients with a history of IHD or stroke were
more likely to die from other causes than prostate cancer,
than patients without such history (Table 2).
Compared with patients without preexisting IHD the
crude HR for patients with preexisting IHD was 1.25
(95% CI 1.20-1.31). For patients with preexisting stroke,
crude HR was 1.57 (95% CI 1.46-1.69). After adjusting
for age, stage, calendar period, and other comorbidities,
both HRs decreased substantially (IHD 1.05, 95% CI
1.00-1.10, and stroke 1.20, 95% CI 1.12-1.30; Table 3).
For prostate cancer patients below 60 years of age, pre-
existing IHD was associated with a lower mortality com-
pared with patients without IHD or stroke (adjusted HR
of 0.97, 95% CI 0.73-1.29; Table 3). This pattern was
similar for patients aged 60 to 70 years (adjusted HR of
0.94, 95% CI 0.84-1.06), whereas patients older than 70
years of age with preexisting IHD had increased mortal-
ity (Table 3). In all age groups, prostate cancer patients
with preexisting stroke had increased mortality com-
pared with those without IHD or stroke.
Preexisting IHD did not affect mortality in prostate
cancer patients without any other comorbidities
(adjusted HR 0.99, 95% CI 0.92-1.07; Table 4) whereas
prostate cancer patients with preexisting stroke and no
other comorbidity had 42% higher mortality compared
with prostate cancer patients without any comorbidity
(adjusted HR 1.42, 95% CI 1.25-1.62; Table 4). We
found no substantial difference in mortality between
men diagnosed with IHD or stroke within one year
before prostate cancer diagnosis and those diagnosed 2-
10 years before prostate cancer diagnosis (data not
shown).
Discussion
In this nationwide cohort study of more than 30,000
prostate cancer patients, we found that preexisting IHD
had only minimal impact on overall mortality, whereas
prostate cancer patients with preexisting stroke had
higher mortality than those without IHD or stroke.
For patients below70 years of age we observed better
survival for patients with preexisting IHD compared with
those without IHD. There are several possible explana-
tions of why prostate cancer patients with IHD had better
survival than prostate cancer patients without IHD.
Because of their cardiovascular disease, these patients
were probably in closer contact with the health care sys-
tem, and were more concerned about their health which
could lead to prostate cancer diagnosis at an earlier stage.
We found, however, a higher prevalence of localized
tumours in patients without IHD or stroke in all three
age groups (data not shown), arguing against such sur-
veillance bias. Other possible explanations include the
beneficial effect of potential lifestyle changes after cardio-
vascular disease diagnosis (e.g. smoking cessation,
increased exercise, weight loss) and the use of secondary
medical prophylaxis, such as statins, which might be
associated with reduced risk of advanced prostate cancer
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medical treatment this intriguing relationship could not
be further explored.
We did not find a similar effect in patients with preex-
isting stroke; in contrast, these patients had substantially
higher mortality than patients without IHD or stroke.
We observed the largest increase in mortality among
patients with preexisting stroke without any other
comorbidities.
Our study revealed a considerable increase in the pre-
valence of IHD or stroke among prostate cancer patients
during the study period. This is consistent with the gen-
eral increase in prevalence of comorbidity among Danish
cancer patients over the last decade [22-25]. Possibly,
patients may be more likely to have a PSA test now than
earlier during follow-up visits for IHD or stroke, which
has resulted in more patients with IHD or stroke to be
diagnosed with prostate cancer in recent years.
We cannot exclude the possibility that IHD or stroke
patients who are diagnosed with prostate cancer present
a selected group of patients, since these patients have
actually survived their cardiovascular disease. This may
bias the estimates towards the null and thus partly
explain why the difference in mortality between those
with and those without a history of cardiovascular disease
is not larger than observed in this study.
Choice of treatment of prostate cancer is determined
by many factors such as age, D’Amico risk group (PSA,
Table 2 Characteristics of the 30,721 prostate cancer patients diagnosed between 1997 and 2008
Characteristics Prostate cancer
patients with IHD n
(%)
Prostate cancer
patients with stroke n
(%)
Prostate cancer patients without
cardiovascular disease n (%)
Entire
cohort n
(%)
No. of patients 4,276 (14) 1,331 (4) 25,114 (82) 30,721
(100)
Age at prostate cancer diagnosis, yr
30-59 173 (4) 53 (4) 2,504 (10) 2,730 (9)
60-69 1,082 (25) 284 (21) 8,202 (33) 9,568 (31)
70-79 1,920 (45) 576 (43) 9,281 (37) 11,777 (38)
80+ 1,101 (26) 418 (32) 5,127 (20) 6,646 (22)
Comorbidity level
Score* none (0) 1,982 (46) 467 (35) 18,148 (72) 20,597 (66)
Score moderate (1-2) 1,650 (39) 647 (49) 5,791 (23) 8,088 (27)
Score high (> 2) 644 (15) 217 (16) 1,175 (5) 2,036 (7)
Stage
I Localized 1,022 (24) 299 (23) 6,743 (27) 8,064 (26)
ll Regional 686 (16) 196 (15) 4,014 (16) 4,896 (16)
Ill Distant 914 (21) 311 (23) 5,260 (21) 6,485 (21)
Unknown 1,654 (39) 525 (39) 9,097 (36) 11,276 (37)
Years from cardiovascular disease to
prostate cancer
0-1 1,278 (30) 375 (28) - -
2-10 2,998 (70) 956 (72) - -
Period of prostate cancer diagnosis
1997-2000 942 (22) 250 (19) 6,093 (24) 7,285 (24)
2001-2004 1,378 (32) 445 (33) 7,721 (31) 9,544 (31)
2005-2008 1,956 (46) 636 (48) 11,300 (45) 13,892 (45)
Total number of deaths during study
period
2,067 732 11,052 13,851
Prostate cancer 1,204 418 7,530 9,152
Cardiovascular diseases 450 155 1,213 1,818
Other causes 413 159 2,309 2,881
Number of years at risk (years from
diagnosis to death or December 31
st 2008)
11,564 3,201 74,922 89,687
Cause of death per 1,000 years at risk
Prostate cancer 104 131 101 102
Cardiovascular diseases 39 48 16 20
Other causes 36 50 31 32
*Level of Charlson Comorbidity index score (not including IHD, stroke, and prostate cancer) IHD = ischemic heart disease
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also influence which treatment a patient is offered. Pre-
v i o u sr e s e a r c ho nt h i st o p i ch a ss h o w nt h a tp r o s t a t e
cancer patients with comorbidities are often offered
nonsurgical/conservative treatment [4,7-9].
In the present study we found that preexisting stroke
increased mortality to a significantly higher degree than
preexisting IHD, which suggest a potential importance
of differentiating between various kinds of comorbid-
ities. When decisions are made about radical treatment
of prostate cancer the type of comorbidity could be rele-
vant to consider and not just the overall burden of
comorbidities as expressed in the Charlson score.
The major strengths of our study were its large size,
the virtually complete follow-up, and the ten year obser-
vation period before prostate cancer diagnosis to identify
hospital-diagnosed comorbidity for each prostate cancer
patient. The validity of the recorded diagnoses is crucial
for the reliability of our findings. The registration of
prostate cancers is thought to be virtually complete
since free health care is available to all residents in Den-
mark: guaranteeing free access to hospitals and essen-
tially eliminates all private inpatient or outpatient
treatment of prostate cancer [16]. The positive
predictive value of ischemica n du n s p e c i f i e ds t r o k ei n
the National Patient Registry has previously been esti-
mated to be above 80% [26], and similar positive predic-
tive values have been found for IHD [27,28].
Study limitations include use of a modified version of
the Charlson Comorbidity index to control for confound-
ing by other comorbidities, and it is unlikely that the
index controls for confounding as effectively as clinical
data [29]. Unfortunately, our study did not include infor-
mation on prognostic lifestyle factors such as smoking or
obesity or clinical data such as Gleason score, PSA, and
treatments for prostate cancer and cardiovascular dis-
eases which may have further informed our estimates.
Conclusions
Our results showed that preexisting IHD had minimal
impact on mortality following prostate cancer, whereas
mortality was 20% higher in prostate cancer patients
with preexisting stroke compared to those without IHD
or stroke and even 42% higher for prostate cancer
patients with preexisting stroke and no other comorbid-
ities. These results highlight the importance of differen-
tiating between various comorbidities when decisions
are made on prostate cancer treatment.
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Figure 1 Kaplan-Meier survival curves. Kaplan-Meier curves showing survival probability of 30,721 prostate cancer patients by preexisting
ischemic heart disease (IHD) or stroke status.
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